Overview

Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT

Status:
Completed
Trial end date:
2018-10-16
Target enrollment:
Participant gender:
Summary
To examine whether the occurrence of oral mucositis can be reduced by dental oral management in patients by comparing the use of dental oral management through instruction by dental and oral surgeons (dental oral management group) and an observation group (brushing instruction only group) in a randomized, controlled study in females that are using everolimus for estrogen receptor-positive, hormone therapy-resistant refractory breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Comprehensive Support Project for Oncology Research
Collaborator:
Novartis Pharmaceuticals
Treatments:
Everolimus
Sirolimus